Quick answers
- What is Trientine used for?
- The FDA-approved label (Syprine, Bausch Health US LLC, September 1, 2020) says: “Syprine is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with Syprine is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. Syprine and penicillamine cannot be considered interchangeable. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Trientine have a boxed warning?
- No. None of the 8 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Trientine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Trientine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Trientine?
- 8 companies list prescription products of Trientine in the FDA NDC Directory, including Rising Pharma Holdings, Inc., Navinta LLC and Camber Pharmaceuticals, Inc..
What Trientine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Syprine is indicated in the treatment of patients with Wilson’s disease who are intolerant of penicillamine. Clinical experience with Syprine is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient’s dose have not been well defined. Syprine and penicillamine cannot be considered interchangeable. …
— FDA label: Syprine, Bausch Health US LLC, effective September 1, 2020. Read the full label on DailyMed →
The FDA has 8 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 8 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| trientine hydrochloride 250 mg capsule | Generic | $2.30 per capsule |
NADAC list of November 4, 2026; these prices took effect on July 22, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Rising Pharma Holdings, Inc.2 products
- Navinta LLC1 product
- Camber Pharmaceuticals, Inc.1 product
- Par Health USA, LLC1 product
- Novadoz Pharmaceuticals LLC1 product
- Dr.Reddys Laboratories Inc1 product
- Bausch Health US, LLC1 product
- Orphalan SA1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA019194 SYPRINE | Bausch | November 8, 1985 | 8, latest March 3, 2015 2015: Manufacturing (CMC) · 2001: Manufacturing (CMC) · 2001: Labeling |
| NDA215760 CUVRIOR | Orphalan | April 28, 2022 | — |
Generic approvals (6)
- ANDA211251Navinta LLC · January 16, 2019
- ANDA211134Msn · May 22, 2019
- ANDA211076DR Reddys · July 3, 2019
- ANDA210096Ph Health · September 25, 2019
- ANDA212238Rising · February 20, 2020
- ANDA216356Hetero Labs Ltd III · June 23, 2022
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Syprine, Bausch Health US LLC, effective September 1, 2020; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →